Liver Toxicity Risk Management Should Consider Timing Of Safety Signal, FDAer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Surveillance strategies should take into account whether drug-induced hepatotoxicity is “front-loaded” soon after initiating therapy or after a longer-term exposure threshold has been reached, Division of Drug Risk Evaluation Director Avigan says.